← Mirum Pharmaceuticals, Inc. (MIRM) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Mirum Pharmaceuticals, Inc. (MIRM)
Pharmaceutical Preparations · market cap $5.8B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-15 (est.)
Phase 3
Pipeline
13
programs
Upcoming events
6
next 90d+
Dossier
Ready
cached
Mirum Pharmaceuticals (MIRM) is a ~$7.4B market-cap rare-disease hepatology specialist with 355 employees and a diversified pipeline anchored by maralixibat (Phase 3, biliary atresia) and brelovitug (multiple Phase 3 arms, chronic hepatitis D). Revenue has grown from $19M in 2021 to $521M in 2024–2025, though the company still posted a $23M net loss in 2025. The next 12 months are unusually catalyst-dense, with two Phase 3 readouts of importance-9/10 expected before year-end 2026.
The catalyst path
- 2026-10-15 (est.)Phase 3 · Maralixibatimp 9/10
- 2026-11-03 (est.)Earningsimp 5/10
- 2027-01-15 (est.)Phase 2 · Volixibatimp 7/10
- 2027-06-15 (est.)Phase 3 · Brelovitug 900 mgimp 9/10
- 2027-06-30 (est.)Phase 3 · Bulevirtide 2 mg and Brelovitug - 300 mgimp 9/10
- 2027-08-31 (est.)Phase 3 · Brelovitug (BJT-778)imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Volixibat | Phase 2 | Primary Biliary Cholangitis |
| Maralixibat | Phase 3 | Biliary Atresia |
| LUM001 (Maralixibat) | Phase 2 | Alagille Syndrome |
| Cholic acid | Phase 3 | Inborn Errors of Bile Acid Synthesis |
| Cholic Acids | Phase 3 | Infantile Refsum's Disease |
| Ursodeoxycholic Acid | Phase 2 | PBC |
| Low dose of MRM-3379 | Phase 2 | Fragile X Syndrome |
| LUM001 | Phase 2 | Alagille Syndrome |
| Blinded CDCA 250 mg TID | Phase 3 | CTX |
| Brelovitug 900 mg | Phase 3 | Chronic Hepatitis D Infection |
| Brelovitug 300 mg | Phase 3 | Chronic Hepatitis D Infection |
| Bulevirtide 2 mg and Brelovitug - 300 mg | Phase 3 | Chronic Hepatitis D Infection |
| Brelovitug (BJT-778) | Phase 3 | Chronic Hepatitis D |
Price & technical context
3-month
-32.0%
6-month
-11.9%
12-month
+13.6%
52-wk range
$64.10–$128.57
vs 50-day MA
-15.5%
vs 200-day MA
-15.6%
Realized vol
46.8%
Max drawdown
-35.5%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MIRM (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 13 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.